LON:AGY

Allergy Therapeutics (AGY) Share Price, News & Analysis

Allergy Therapeutics logo
GBX 1.13 -0.10 (-8.08%)
As of 11/20/2026 12:33 PM Eastern

About Allergy Therapeutics Stock (LON:AGY)

Advanced

Key Stats

Today's Range
1.10
▼
1.25
50-Day Range
1.13
▼
5.20
52-Week Range
1.10
▼
12.10
Volume
30.37 million shs
Average Volume
660,597 shs
Market Capitalization
£71.30 million
P/E Ratio
N/A
Dividend Yield
8.33%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development. Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group has achieved over 9% compound annual growth since formation and employs c.500 employees.

Receive AGY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allergy Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AGY Stock News Headlines

Allergy Therapeutics plc Announces Board Resignations
Are Tesla and SpaceX Going Bankrupt?
Tesla and SpaceX shares crashed right after Democrats took the House and the Senate in the midterm election. Elon Musk backed President Trump and donated millions to Republicans, and many believe he will become a political target. Brownstone Research founder Jeff Brown has seen Musk's new technology on camera. He says he is more convinced than ever that nothing can stop the coming Elon Musk revolution.tc pixel
Allergy Therapeutics to go private
Proposed Cancellation of Admission
See More Headlines

AGY Stock Analysis - Frequently Asked Questions

Allergy Therapeutics' stock was trading at GBX 11.20 at the start of the year. Since then, AGY stock has decreased by 89.9% and is now trading at GBX 1.13.

Allergy Therapeutics plc (LON:AGY) released its earnings results on Tuesday, March, 31st. The company reported GBX (0.38) earnings per share (EPS) for the quarter. The firm earned £36.28 million during the quarter. Allergy Therapeutics had a negative net margin of 86.04% and a positive trailing twelve-month return on equity of 1,684.19%.

Shares of AGY stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Allergy Therapeutics investors own include Sosandar (SOS), Esperion Therapeutics (ESPR), Bristol Myers Squibb (BMY), Adocia (ADOCY), Alnylam Pharmaceuticals (ALNY), Anglo African Oil & Gas (AAOG) and Ariana Resources (AAU).

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
LON:AGY
CIK
N/A
Fax
N/A
Employees
612
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
GBX (0.97)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
-30.7
Net Income
-£52.59 million
Net Margins
-86.04%
Pretax Margin
N/A
Return on Equity
1,684.19%
Return on Assets
-34.76%

Debt

Debt-to-Equity Ratio
-646.31
Current Ratio
2.29
Quick Ratio
1.48

Sales & Book Value

Annual Sales
£59.87 million
Price / Sales
1.19
Cash Flow
GBX 0.31 per share
Price / Cash Flow
3.66
Book Value
GBX 0.10 per share
Price / Book
11.41

Miscellaneous

Outstanding Shares
6,332,530,000
Free Float
N/A
Market Cap
£71.30 million
Optionable
Not Optionable
Beta
0.84
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (LON:AGY) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners